Last reviewed · How we verify
Ketorolac, Nepafenac
Ketorolac and Nepafenac, marketed by Innovative Medical, are nonsteroidal anti-inflammatory drugs (NSAIDs) with a well-established presence in the market. A key strength is the protection provided by the key composition patent, which is set to expire in 2028, offering a period of exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.
At a glance
| Generic name | Ketorolac, Nepafenac |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery (PHASE2)
- Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% (NA)
- Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (PHASE3)
- A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief (PHASE4)
- Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery (PHASE4)
- Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema (PHASE2)
- NSAIDs and PGE2 Levels in Vitrectomy Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac, Nepafenac CI brief — competitive landscape report
- Ketorolac, Nepafenac updates RSS · CI watch RSS
- Innovative Medical portfolio CI